LL-37

LL-37 is a 37-amino-acid cationic antimicrobial peptide that represents the only known member of the cathelicidin family in humans. It is the active C-terminal fragment of the precursor protein hCAP-18, which is expressed by neutrophils, macrophages, epithelial cells, and skin keratinocytes. LL-37 represents the frontline of the innate immune response: it directly kills bacteria, fungi, and enveloped viruses while simultaneously modulating inflammatory signaling. Its research applications span infectious disease, wound healing, autoimmunity, and even cancer, as its effects on cellular proliferation and immune signaling are multidirectional.

LL-37 exerts direct antimicrobial activity by disrupting bacterial and viral cell membranes through electrostatic interaction — its cationic structure binds to negatively charged lipopolysaccharide (LPS) on gram-negative bacteria and lipoteichoic acid (LTA) on gram-positive bacteria, causing membrane destabilization and cell lysis. This mechanism is difficult for bacteria to develop resistance against. Beyond direct killing, LL-37 acts as an immune modulator: it binds and neutralizes LPS, preventing the endotoxin-mediated septic shock cascade. It stimulates chemokine release from epithelial cells (CXCL8, MCP-1), recruiting neutrophils and monocytes to infection sites. It activates formyl peptide receptor-like 1 (FPRL1), promoting wound healing and angiogenesis. LL-37 also binds DNA and RNA complexes, acting as a pattern-recognition trigger for TLR-9 and TLR-7, bridging innate and adaptive immunity. In cancer research, it demonstrates both pro-apoptotic and pro-proliferative effects depending on cancer type and concentration.

LL-37 research spans antimicrobial activity, wound healing, and immune modulation. Laboratory studies have established its membrane-disrupting mechanism against gram-positive and gram-negative bacteria, fungi, and enveloped viruses. Clinical trials investigating topical LL-37 for wound care and venous leg ulcers have been completed in Sweden. The University of Lund has conducted human volunteer studies confirming its effects on wound re-epithelialization. LL-37's role in psoriasis pathogenesis was established through studies showing that LL-37 complexed with self-DNA activates plasmacytoid dendritic cells via TLR-9 — a landmark finding linking antimicrobial peptides to autoimmunity. Research in lupus models has similarly implicated LL-37/DNA complexes in TLR activation.

Antimicrobial/Infection Support Protocol: LL-37 100 mcg SC daily for 4 weeks during active infection research. Combined Innate Immune Stack: LL-37 100 mcg/day + Thymosin Alpha-1 1.6 mg twice weekly for broad-spectrum immune activation targeting both innate (LL-37) and adaptive (Tα1) arms. Wound Healing Topical Protocol: 0.5% LL-37 topical gel applied twice daily to wound bed + BPC-157 500 mcg SC daily for accelerated repair.

LL-37 has significant dose-dependent pro-inflammatory activity — at higher doses, it can intensify local inflammatory reactions. Injection site inflammation, redness, and tenderness are the most consistently reported effects. Systemic inflammatory responses including flu-like symptoms, mild fever, and fatigue can occur, particularly at doses above 100 mcg/day, due to its innate immune activating properties. In autoimmune contexts, LL-37 can be problematic: elevated endogenous LL-37 is implicated in psoriasis pathogenesis (it activates plasmacytoid dendritic cells via TLR-9, triggering the psoriatic cytokine cascade) and lupus. Individuals with autoimmune conditions should approach LL-37 supplementation with extreme caution. Paradoxically, in cancer research, LL-37 has shown both anti-tumor and tumor-promoting effects — its net effect depends heavily on tissue type and microenvironment.

Store lyophilized LL-37 at -20°C for long-term storage, protected from moisture and light. Reconstitute with sterile water or bacteriostatic water and store reconstituted solution at 2–8°C, using within 7–14 days. LL-37 is susceptible to aggregation at higher concentrations — vortex gently (do not shake) and allow to equilibrate to room temperature before injection. Topical formulations should be stored at room temperature in opaque containers.